Stockscreener 앱 받기
11.50
1.54%
-0.18
시간 외 거래:
11.51
0.010
+0.09%
전일 마감가:
$11.68
열려 있는:
$11.53
하루 거래량:
119.66K
Relative Volume:
0.70
시가총액:
$393.93M
수익:
$7,000
순이익/손실:
$-38.96M
주가수익비율:
-12.37
EPS:
-0.9296
순현금흐름:
$-18.34M
1주 성능:
-5.12%
1개월 성능:
+6.09%
6개월 성능:
-14.50%
1년 성능:
-26.56%
1일 변동 폭
$11.24
$11.85
1주일 범위
$11.19
$12.48
52주 변동 폭
$9.85
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
명칭
Benitec Biopharma Inc
전화
(510) 780-0819
주소
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.50 | 400.10M | 7,000 | -38.96M | -18.34M | -0.9296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-09-12 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Piper Sandler | Overweight |
| 2020-10-05 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | 개시 | Ladenburg Thalmann | Buy |
| 2016-02-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-12-31 | 재확인 | Maxim Group | Buy |
| 2015-09-16 | 재확인 | Maxim Group | Buy |
모두보기
Benitec Biopharma Inc 주식(BNTC)의 최신 뉴스
BNTC SEC FilingsBenitec Biopharm 10-K, 10-Q, 8-K Forms - Stock Titan
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Risk Recap: What is the dividend yield of Benitec Biopharma Inc2026 Setups & Low Drawdown Trading Strategies - baoquankhu1.vn
Portfolio Recap: Is Benitec Biopharma Inc stock a good dividend stockDollar Strength & High Accuracy Swing Trade Signals - baoquankhu1.vn
Jerel A. Banks, MD, PhD, on Evaluating Gene Therapy BB-301 for OPMD-Related Dysphagia - CGTLive®
Surprises Report: Can Benitec Biopharma Inc maintain its current growth rate2026 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(BNTC) Risk Channels and Responsive Allocation - Stock Traders Daily
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for - The Manila Times
Breakfast talk to show OPMD swallowing gains from gene therapy BB-301 - Stock Titan
Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright - Defense World
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Developmen... - Sahm
Benitec Biopharma Inc. (BNTC) Competitors - Meyka
Cowen Reiterates Buy on Benitec Biopharma (BNTC) March 2026 - Meyka
Benitec Biopharma : Corporate Presentation, March 2026 - marketscreener.com
Benitec BioPharma stock maintains Buy rating on positive trial data By Investing.com - Investing.com South Africa
Benitec BioPharma stock maintains Buy rating on positive trial data - Investing.com
BNTC: HC Wainwright & Co. Reiterates Buy Rating on Benitec Bioph - GuruFocus
Benitec reports interim results from gene therapy trial - Investing.com Nigeria
Benitec Biopharma (BNTC) Reports Encouraging Interim Results fro - GuruFocus
Benitec's BB-301 delivers durable swallowing gains in OPMD - Stock Titan
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Bitget
Benitec Biopharma Stock Pre-Market (+7.1%): Analyst Raises EPS Forecasts - Trefis
Sentiment Recap: What is the Moat Score of Benitec Biopharma IncJuly 2025 Outlook & Stock Timing and Entry Methods - baoquankhu1.vn
New Highs: How liquid is Benitec Biopharma Inc stockJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
HC Wainwright Expects Higher Earnings for Benitec Biopharma - Defense World
HC Wainwright Issues Optimistic Forecast for BNTC Earnings - MarketBeat
Levels Update: Is Benitec Biopharma Inc exposed to political riskTreasury Yields & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Research Analysts Offer Predictions for BNTC Q1 Earnings - Defense World
Analysts Issue Forecasts for BNTC Q1 Earnings - MarketBeat
(BNTC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Benitec Biopharma Inc. (BNTC) - DirectorsTalk Interviews
Benitec BioPharma stock rating maintained on gene therapy data - Investing.com Nigeria
Benitec BioPharma stock rating maintained on gene therapy data By Investing.com - Investing.com Australia
Benitec Biopharma Announces Acceptance of Late- Breaking - GlobeNewswire
Durable BB-301 responses in muscular dystrophy to be detailed at MDA 2026 - Stock Titan
Benitec Biopharma (BNTC) Stock Analysis: Unpacking A 125% Potential Upside - DirectorsTalk Interviews
Liquidity Mapping Around (BNTC) Price Events - Stock Traders Daily
What insider trading reveals about Benitec Biopharma Inc. stockJuly 2025 Opening Moves & Verified Swing Trading Watchlists - mfd.ru
Growth Value: What insider trading reveals about Benitec Biopharma Inc. stockMarket Trend Summary & Smart Money Movement Alerts - mfd.ru
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Yahoo Finance
Hedge funds owners may consider drastic measures as Benitec Biopharma Inc.'s (NASDAQ:BNTC) recent US$60m drop adds to long-term losses - simplywall.st
Wall Street Zen Downgrades Benitec Biopharma (NASDAQ:BNTC) to Sell - MarketBeat
BNTC PE Ratio & Valuation, Is BNTC Overvalued - Intellectia AI
Benitec Biopharma (NASDAQ:BNTC) Announces Quarterly Earnings Results - MarketBeat
Benitec Biopharma Inc. (BNTC) Investor Outlook: Analyst Ratings Signal a Promising 104.58% Upside Potential - DirectorsTalk Interviews
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
Benitec Biopharma Q2 net loss widens - TradingView
BENITEC BIOPHARMA ($BNTC) Releases Q2 2026 Earnings - Quiver Quantitative
Benitec Biopharma Inc. SEC 10-Q Report - TradingView
Benitec (BNTC) Advances BB-301 Program with Promising Safety and Efficacy - GuruFocus
Benitec Biopharma Inc (BNTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):